Start with what ASHRAE 241 controls
- ASHRAE 241 infection risk mitigation
- For this article, ASHRAE 241 infection risk mitigation means using ASHRAE Standard 241 as the regulatory and engineering frame for reducing exposure to infectious aerosols through air-system design, installation, commissioning, operation, maintenance, and infection risk management mode decisions.1,4
ASHRAE describes Standard 241 as establishing minimum requirements aimed at reducing disease-transmission risk from infectious aerosols in new buildings, existing buildings, and major renovations. CDC characterizes the standard as compliance-focused and tied to equivalent clean airflow per person during infection risk management mode, while CDC ventilation guidance remains voluntary unless adopted by an authority with legal jurisdiction.1,4
Separate the chamber method from the installed use
| Use case | Method frame to consider | Main scoping question |
|---|---|---|
| Portable household room air cleaner | ANSI/AHAM AC-5 using an aerobiology test chamber | Does the portable unit reduce concentration and viability of experimentally generated bioaerosols in the chamber condition? |
| Commercial or industrial in-room air cleaner | ANSI/ASHRAE Standard 185.3 test-chamber method | Does the in-room system remove or inactivate microorganism bioaerosol under the chamber method and selected operating mode? |
| In-duct UV or air-handling-unit installation | ASHRAE 185.1 or ISO 15714 where applicable, plus ASHRAE 241 safety requirements | Does the in-duct configuration inactivate airborne microorganisms at the airflow, residence time, and UV exposure condition being claimed? |
| HVAC recirculation or custom recirculating chamber study | Project-specific protocol aligned to the accepted consensus method where possible | Does the chamber reproduce the recirculation path, mixing, bypass, upstream and downstream sampling, and installed operating mode? |
ASHRAE Addendum a to Standard 241-2023 added references for air-cleaning effectiveness and safety determinations, including AHAM AC-5 and ASHRAE 185.3 as permitted effectiveness standards in the appendix context. AHAM AC-5 is written for portable household air cleaners using an aerobiology test chamber, while ASHRAE identifies Standard 185.3 as a method for commercial and industrial in-room air-cleaning devices and systems in a microorganism bioaerosol test chamber.2,3,5
For HVAC recirculation, the protocol should not borrow an in-room result without checking the airflow path. Recirculation studies need defined supply and return conditions, mixing or bypass assumptions, air changes or clean airflow basis, upstream and downstream sampling locations, challenge stability, and the actual operating mode used during the run.2,3,4
GLP is a data-integrity decision
GLP should be decided during study design, not after a favorable result. EPA's GLP regulations in 40 CFR Part 160 apply to studies intended to support pesticide research or marketing permits, and the current eCFR text identifies protocol, study director, quality assurance unit, raw data, equipment calibration, standard operating procedures, final reporting, and record-retention expectations. FDA's 21 CFR Part 58 provides a related GLP framework for nonclinical laboratory studies submitted to FDA.6,7
- If the data may support an EPA-regulated air purifier, filter, UV unit, or air treatment device with antimicrobial or public-health claims, decide whether EPA GLP applies before finalizing the protocol.6,8
- If the study supports screening, engineering development, or comparison only, the report can still use controlled methods and traceable records without representing the study as GLP-compliant.6,7
- If a sponsor needs GLP, the protocol, deviations, raw data, organism records, calibration records, chain of custody, QA inspections, and final report language should be aligned from the start.6
Safety and claim language are part of the evidence
Bioaerosol efficacy is only one side of the regulatory question. EPA identifies air purifiers, filters, UV light units, and air treatment devices as examples of pesticide devices when they make pest-control or microorganism-reduction claims, and it warns that device labels and advertising can be false or misleading if efficacy claims are not supportable.8
Safety review should match the technology. EPA and CDC discuss ozone and ion-generating air-cleaner concerns, CDC recommends verifying UL 2998 certification when considering products that may generate ozone, and ASHRAE 241's addendum links air-cleaning effectiveness with safety-element testing when applicable standards are used.2,4,9
Bioaerosol laboratory safety needs its own controls. CDC and NIH BMBL guidance frames biosafety around protocol-driven risk assessment, which means the organism, concentration, aerosol generation, sampling train, decontamination, containment, personnel protection, and waste handling should be selected before live challenge work begins.10
What to define before requesting testing
- Name the compliance target: ASHRAE 241 design support, product-development screening, EPA claim support, customer comparison, or another documented decision.1,6,8
- Define the operating configuration: portable in-room, commercial in-room, in-duct, air-handling-unit, HVAC recirculation, or custom chamber recirculation.2,3,5
- Select the measurement basis before testing, such as viable bioaerosol reduction, removal, inactivation, microbial clean air delivery, equivalent clean airflow, pressure drop, airflow, ozone, or byproduct monitoring.2,4,5,9
- Decide whether GLP applies and whether the report must include a GLP compliance statement, non-GLP statement, QA records, raw data reconstruction, and record-retention commitments.6,7